期刊文献+

血清sST-2与2型糖尿病患者冠状动脉斑块的相关性研究 被引量:2

The relationships between serum soluble ST2 levels and coronary atherosclerosis plaque in patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的 探讨2型糖尿病患者血清可溶性人基质裂解素(s ST-2)与冠状动脉粥样硬化、斑块负荷和斑块结构之间的相关性。方法 行冠脉CTA检测的188例2型糖尿病患者,根据冠脉CTA结果分为非冠状动脉粥样硬化组93例和冠状动脉粥样硬化组95例,ELISA法检测患者血清s ST-2水平。结果 冠状动脉粥样硬化组患者血清s ST-2水平明显高于非冠状动脉硬化组(P〈0.05),s ST-2与BMI、hs-CRP、斑块数目、病变血管/节段数目、斑块数量和钙化斑块呈正相关性(P〈0.05);s ST-2水平是校正后2型糖尿病冠状动脉粥样硬化的独立预测因子(P〈0.05,OR为1.002,95%CI为1.000-1.003)。结论 s ST-2与2型糖尿病患者发生冠状动脉粥样硬化有相关性。 Objective To explore the relationship between serum soluble ST2 and coronary atherosclerosis,coronary plaque burden and plaque structures in patients with type 2 diabetes mellitus (DM). Methods A total of 188 patients diagnosized type 2 DM undergoing planned coronary computed tomography angiography (CTA) were enrolled in this observational study. According to the CTA images,the patients were divided into non - coronary artery diseases group andcoronary artery diseases group. The level of sST2 were detected using ELISA kit. Results The sST-2 concentrations were significantly higher in the CAD group than in the non- CAD group(P 〈0. 05). The levels of sST- 2 were correlated positively with BMI, high - sensitivity C -reactive protein, the total number of diseased vessels,the number of plaques and the calcified plaque type(P 〈0. 05). sST -2 were found to be a significant independent predictor of coronary atherosclerosis in type 2 diabetic patients (P〈0.05;odds ratio , 1.002 ;95% confidence interval,1.000-1.003). Condusions sST-2 is associated with coronary atherosclerosis in type 2 diabetic patients.
出处 《宁夏医学杂志》 CAS 2016年第7期585-587,共3页 Ningxia Medical Journal
关键词 冠状动脉粥样硬化 2型糖尿病 血清可溶性人基质裂解素 冠脉CT血管成像 Coronary atherosclerosis Diabetes mellitus Soluble ST2 Coronary CT angiography
  • 相关文献

参考文献3

二级参考文献19

  • 1Escobar E. Hypertension and coronary heart disease. Journal of human hypertension 2002; 16 Suppl 1: $61-3.
  • 2Lawes CM, Vander Hoorn S, Rodgers A, International Society of H. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371(9623): 1513-8.
  • 3Lloyd-Jones DM, Leip EP, Larson MG, et al. Novel approach to examining first cardiovascular events after hypertension onset. Hypertension 2005; 45(1 ): 39-45.
  • 4Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European heart journal 2013; 34(38): 2949-3003.
  • 5Miller AM, Liew FY. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. Pharmacology & therapeutics 2011; 131(2): 179-86.
  • 6Willems S, Hoefer I, Pasterkamp G. The role of the lnterleukin 1 receptor-like 1 (ST2) and lnterleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment. Minerva medica 2012; 103(6): 513-24.
  • 7Miller AM. Role of IL-33 in inflammation and disease. Journal of inflammation 2011; 8(1): 22.
  • 8Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. The Journal of experimental medicine 2008; 205(2): 339-46.
  • 9Eggers KM, Armstrong PW, Califf RM, et aL ST2 and mortality in non-ST-segment elevation acute coronary syndrome. American heart journal 2010; 159(5): 788-94.
  • 10Bauters C. [Pathophysiology of coronary artery disease]. La Revue du praticien 2008; 58(14): 1523-6.

共引文献7

同被引文献12

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部